论文部分内容阅读
磷脂酰肌醇蛋白聚糖-3(GPC3)对肝细胞癌(HCC)的诊断具有很高的敏感性和特异性,是具有前景的肿瘤标志物.本文的目的是应用抗人-GPC3单克隆抗体7D11(7D11McAb),通过免疫组化(IHC)的方法检测HCC组织中的GPC3蛋白,并初步评价其诊断HCC的临床应用价值.通过对HCC病理组织、正常肝脏组织和胆管细胞癌(ICC)病理组织进行免疫组化染色来评价7D11McAb的可应用性.同时,应用7D11McAb作为检测抗体对40例HCC,7例ICC和50例正常人的血清GPC3进行检测.免疫组化结果显示,GPC3蛋白在85%(34/40)HCC组织高表达,而在正常人和ICC病人的组织中阳性率均为0%(0/50和0/7).血清学检测结果显示,GPC3在HCC,正常人和ICC病人的血清中阳性率分别为:42.5%(17/40),0%(0/50%)和0%(0/7).7D11McAb的制备为GPC3能大规模应用于临床奠定了基础.
Glypican-3 (GPC3) is a promising tumor marker with high sensitivity and specificity for the diagnosis of hepatocellular carcinoma (HCC). The purpose of this paper is to use anti-human-GPC3 monoclonal Antibody 7D11 (7D11McAb) was used to detect the GPC3 protein in HCC tissues by immunohistochemistry (IHC) and to evaluate its clinical value in the diagnosis of HCC.Through HCC pathology, normal liver tissue and cholangiocarcinoma (ICC) Immunohistochemical staining was used to assess the applicability of 7D11McAb.Meanwhile, 7D11McAb was used as a detection antibody to detect serum GPC3 in 40 HCCs, 7 ICCs and 50 normal controls.The results of immunohistochemistry showed that GPC3 protein was The positive rates were 0% (0/50 and 0/7) in 85% (34/40) HCC tissues and 0% (0/50 and 0/7) in normal and ICC tissues, respectively. Serological tests showed that GPC3 was positive in HCC, And ICC patients were 42.5% (17/40), 0% (0/50%) and 0% (0/7), respectively. The preparation of 7D11McAb laid the foundation for the large-scale application of GPC3 in clinical practice .